Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Remimazolam Safety and PK/PD Study
NCT03329014Phase 1Completed
- Sponsor
- PAION AG
- Start
- May 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of remimazolam in Procedural sedation (PS) (9 arms), sponsored by PAION AG. Primary endpoint: Number of Participants with Treatment-related Adverse Events. Started May 2017; status: completed.
02
Drugs
remimazolam
03
Conditions
Procedural sedation (PS)
Beyond the preview
Go deeper on NCT03329014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329014.